Dravet Syndrome (DS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Dravet Syndrome (DS) Marketed and Pipeline Drugs Report Overview
Dravet syndrome is also known as severe myoclonic epilepsy of infancy (SMEI). It is a rare and severe form of epilepsy that typically begins in the first year of life. The exact cause of Dravet syndrome is usually genetic. However, seizures in affected individuals can be triggered by various factors including fever, infections, and sometimes vaccinations. These triggers can lead to prolonged and potentially life-threatening seizures known as status epilepticus. Genetic testing is commonly used to diagnose Dravet syndrome.
Key Mechanism of Action (Marketed) | · Receptor Agonists
· Ion Channel Blockers · Receptor Antagonists · Enzyme Inhibitors · Transporter Binder · Transporter Inhibitor · Ion Channel Inhibitor |
Key Routes of Administration (Marketed) | · Injection
· Oral |
Key Molecule Types (Marketed) | · Small Molecules |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.a |
The Dravet Syndrome (DS) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, and late-to-mid-stage pipeline products with Phase transition success rate (PTSR) and the likelihood of approval (LoA) for Dravet syndrome (DS). The report also analyzes the clinical and commercial landscapes of DS, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Key Mechanisms of Action (Pipeline) | · Receptor Agonists
· Ion Channel Activators · Enzyme Inhibitors · Receptor Antagonists · Receptor Modulators · Ion Channel Inhibitors · Protein and Peptide Activators |
Key Routes of Administration (Pipeline) | · Injection
· Oral |
Key Molecule Types (Pipeline) | · Biologics
· Small Molecules · Oligonucleotides |
Top Sponsors (Marketed and Pipeline Drugs) | · Takeda Pharmaceutical Co Ltd
· GW Pharmaceuticals Ltd · Zogenix Inc · Stoke Therapeutics Inc · Supernus Pharmaceuticals Inc |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
DS Marketed Drugs Segmentation by Mechanisms of Action
Most of the marketed drugs for Dravet syndrome are receptor agonists by the mechanism of action, followed by ion channel blockers, receptor antagonists, and enzyme inhibitors. Transporter binder, transporter inhibitor, and ion channel inhibitor are the other mechanisms of action.
DS Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of DS Marketed Drugs
DS Marketed Drugs Segmentation by Routes of Administration
All conventional marketed drugs available for Dravet syndrome are mostly administered orally or injected.
DS Marketed Drugs Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of DS Marketed Drugs
DS Marketed Drugs Segmentation by Molecule Types
All conventional marketed drugs available for Dravet syndrome are small molecules.
Buy the Full Report to Know More about the Molecule Types of DS Marketed Drugs
DS Pipeline Drugs Market Segmentation by Mechanisms of Action
Most of the pipeline drugs in the Dravet syndrome landscape are receptor agonists, followed by ion channel activators in terms of mechanism of action. The other MoAs are enzyme inhibitors, receptor antagonists, receptor modulators, ion channel inhibitors, and protein and peptide activators.
DS Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy Full Report to Know More about the MoA of DS Pipeline Drugs
DS Pipeline Drugs Market Segmentation by Routes of Administration
Most pipeline drugs for Dravet syndrome are oral drugs, followed by injection therapies.
DS Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy Full Report to Know More about the RoA of DS Pipeline Drugs
DS Pipeline Drugs Market Segmentation by Molecule Types
Most pipeline drugs for Dravet syndrome are small molecules, followed by biologics. Oligonucleotide molecules in development are fewer in number and in earlier stages of development than the others.
DS Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of DS Pipeline Drugs
DS Marketed and Pipeline Drugs Market – Competitive Landscape
Some of the top sponsors in the DS marketed and pipeline drugs market are Takeda Pharmaceutical Co Ltd, GW Pharmaceuticals Ltd, Zogenix Inc, Stoke Therapeutics Inc, and Supernus Pharmaceuticals Inc. In 2023, Takeda Pharmaceutical Co Ltd leads among the trial sponsors after adding up all the trial phases.
DS Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy Full Report for More Sponsor Insights into the DS Marketed and Pipeline Drugs Market Download A Free Report Sample
Segments Covered in the Report
DS Marketed Drugs Mechanism of Action (Number of Drugs, 2023)
- Receptor Agonists
- Ion Channel Blockers
- Receptor Antagonists
- Enzyme Inhibitors
- Transporter Binder
- Transporter Inhibitor
- Ion Channel Inhibitor
DS Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
DS Marketed Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Small Molecules
DS Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Agonists
- Ion Channel Activators
- Enzyme Inhibitors
- Receptor Antagonists
- Receptor Modulators
- Ion Channel Inhibitors
- Protein and Peptide Activators
DS Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
DS Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologics
- Small Molecules
- Oligonucleotides
Scope
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the DS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which is the leading MoA for DS marketed drugs?
In 2023, most of the marketed drugs for DS are receptor agonists.
-
Which is the leading RoA for DS marketed drugs?
In 2023, most of the marketed drugs for DS are administered orally.
-
Which is the leading MoA for DS pipeline drugs?
In 2023, most of the DS pipeline drugs are receptor agonists.
-
Which is the leading RoA for DS pipeline drugs?
In 2023, most of the drugs in the DS pipeline are administered orally.
-
Which is the leading molecule type for DS pipeline drugs?
In 2023, most of the pipeline drugs for DS are small molecules.
-
Who are the top sponsors for DS marketed and pipeline drugs market?
Some of the top sponsors in the DS marketed and pipeline drugs market are Takeda Pharmaceutical Co Ltd, GW Pharmaceuticals Ltd, Zogenix Inc, Stoke Therapeutics Inc, and Supernus Pharmaceuticals Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.